Literature DB >> 23891745

New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam.

Paul Zarogoulidis1, Ioannis Kioumis, Christos Ritzoulis, Dimitris Petridis, Kaid Darwiche, Konstantinos Porpodis, Dionysis Spyratos, Scott Parrish, Robert Browning, Qiang Li, J Francis Turner, Lutz Freitag, Konstantinos Zarogoulidis.   

Abstract

BACKGROUND: Several aerosol antibiotics are on the market and several others are currently being evaluated. Aim of the study was to evaluate the aerosol droplet size of five different antibiotics for future evaluation as an aerosol administration.
MATERIALS AND METHODS: The nebulizers Sunmist(®), Maxineb(®) and Invacare(®) were used in combination with four different "small <6 ml" residual cups and two "large <10 ml" with different loadings 2-4-6-8 ml (8 ml only for large residual cups) with five different antibiotic drugs (ampicilln-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam). The Mastersizer 2000 (Malvern) was used to evaluate the produced droplet size from each combination
RESULTS: Significant effect on the droplet size produced the different antibiotic (F=96.657, p<0.001) and the residual cup design (F=68.535, p<0.001) but not the different loading amount (p=0.127) and the nebulizer (p=0.715). Interactions effects were found significant only between antibiotic and residual cup (F=16.736, p<0.001). No second order interactions were found statistically significant.
CONCLUSION: Our results firstly indicate us indirectly that the chemical formulation of the drug is the main factor affecting the produced droplet size and secondly but closely the residual cup design.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aerosol; Amikacin (PubChem CID: 37768); Amphotericin B (PubChem CID: 49867934); Antibiotics; Aztreonam (PubChem CID: 5742832); Ciprofloxacin (PubChem CID: 2764); Clindamycin (PubChem CID: 29029); Colistin (PubChem CID: 5311054); Fosfomycin (PubChem CID: 73491); Gentamycin (PubChem CID: 3467); Infection; Levofloxacin (PubChem CID: 149096); Tobramycin (PubChem CID: 36294)

Mesh:

Substances:

Year:  2013        PMID: 23891745     DOI: 10.1016/j.ijpharm.2013.07.040

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil.

Authors:  Haidong Huang; Paul Zarogoulidis; Sofia Lampaki; John Organtzis; Dimitris Petridis; Konstantinos Porpodis; Antonis Papaiwannou; Vasilis Karageorgiou; Georgia Pitsiou; Ioannis Kioumis; Wolfgang Hohenforst-Schmidt; Qiang Li; Kaid Darwiche; Lutz Freitag; Aggeliki Rapti; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 2.  Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Authors:  Eric Wenzler; Dustin R Fraidenburg; Tonya Scardina; Larry H Danziger
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

3.  Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections.

Authors:  Frantiescoli Dimer; Cristiane de Souza Carvalho-Wodarz; Jörg Haupenthal; Rolf Hartmann; Claus-Michael Lehr
Journal:  Pharm Res       Date:  2015-06-26       Impact factor: 4.200

4.  Refractory Burkholderia cepacia bacteraemia from a consolidation pneumonia lasting more than 7 weeks, successfully treated with systemic antibiotics and nebulised meropenem.

Authors:  Bryan Albert Lim; Adelaine Lopez; Joseph Adrian Buensalido
Journal:  BMJ Case Rep       Date:  2019-08-02

Review 5.  Clinical experimentation with aerosol antibiotics: current and future methods of administration.

Authors:  Paul Zarogoulidis; Ioannis Kioumis; Konstantinos Porpodis; Dionysios Spyratos; Kosmas Tsakiridis; Haidong Huang; Qiang Li; J Francis Turner; Robert Browning; Wolfgang Hohenforst-Schmidt; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2013-10-02       Impact factor: 4.162

6.  Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol.

Authors:  Paul Zarogoulidis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Dionysios Spyratos; Georgia Pitsiou; Dimitris Petridis; Athanasia Pataka; Haidong Huang; Qiang Li; Lonny Yarmus; Wolfgang Hohenforst-Schmidt; Nikolaos Pezirkianidis; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2014-08-12       Impact factor: 4.162

7.  Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.

Authors:  Georgia Pitsiou; Paul Zarogoulidis; Dimitris Petridis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Antonis Papaiwannou; Theodora Tsiouda; Wolfgang Hohenforst-Schmidt; Stylianos Kakolyris; Konstantinos Syrigos; Haidong Huang; Qiang Li; J Francis Turner; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2014-10-07       Impact factor: 4.162

8.  Inhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible.

Authors:  Konstantinos Sapalidis; Paul Zarogoulidis; Haidong Huang; Chong Bai; Yuting Wen; Li Wang; Konstantina Boniou; Ilias Karapantzos; Chrysanthi Karapantzou; Michael Karanikas; Vasilis Thomaidis; Christoforos Kosmidis; Chrysanthi Sardeli; Naim Benhassen; Yan-Gao Man; Maria C Florou; Stylianos Mantalovas; Stella Laskou; Dimitris Giannakidis; Charilaos Koulouris; Aikaterini Amaniti; Isaak Kesisoglou; Wolfgang Hohenforst-Schmidt
Journal:  J Cancer       Date:  2018-03-02       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.